Sarepta Wins Exon 51 Composition Patent Rights Over BioMarin

Patent Trial and Appeal Board rules against BioMarin in proceeding to determine who has rights to a composition of matter patent for eteplirsen; last year the board ruled in BioMarin's favor on method of use patent.

A day after FDA approved Sarepta Therapeutics Inc.'s Exondys 51 (eteplirsen), the company won a favorable ruling from the patent office enabling it to obtain a composition of matter patent on the Duchenne muscular dystrophy drug.

The US Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) issued a Sept. 20 order against...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet